Abstract: Objective: To discuss the safety and neuroprotecive effect of early use of dexmedetomidine on patients with severe
craniocerebral injuries. Methods: 62 cases of severe craniocerebral injuries from January 2016 to August 2018 in the department of
neurosurgery intensive care unit in Central Hospital of Yiyang City were studied. They all showed various degrees of restlessness, and
were sedated with intravenous use of dexmedetomidine after admission. Heart rate (HR), respiratory rate (R), blood oxygen saturation
(SaO2) and arterial partial pressure of oxygen (PaO2) before and 30 min, 1, 6, 12, 24 h after medication were recorded, and changes in
interleukins-6 (IL-6) and C-reactive protein (CRP) were analyzed. The drug dosage that sedated the patient to a Ramsay score of 2 to 4
was the maintenance dose. Results: All patients received satisfactory sedation after continuous pumping of dexmedetomidine, and there
was no excessive sedation. SaO2 and PaO2 were significantly increased at 6,12 and 24 hours after the treatment, and the difference was
statistically significant compared with that before treatment (P< 0.05), the R of patients at 6,12 and 24 h after the treatment were
significantly lower than those before the treatment, the difference was statistically significant (P<0.05). Conclusion: Dexmedetomidine
has a satisfactory sedative effect on patients with severe craniocerebral injury, with no respiratory depression, high safety, and could
make the patients be awaked easily when necessary, so it is suitable for short-term sedation on patients with severe craniocerebral
injury and restlessness.

Key words: breath, stress, inflammatory mediator, intracranial hypertension, craniocerebral injury